
This nonprofit is building the ecosystem to cure epidermolysis bullosa
Episode 207
Epidermolysis bullosa, or EB, is one of those diseases that stops you in your tracks the moment you understand it. Skin so fragile that the gentlest touch can cause blisters and open wounds. No cure. And for most of its history, very little serious drug development attention. That's where today's guest comes in. Martin Steiner is Managing Director of DEBRA Research, a non-profit organization with a single-minded mission: to make EB curable. But DEBRA Research isn't a lab. It doesn't run clinical trials or make drugs. What it does is something arguably harder: it builds the ecosystem that makes drug development possible. Funding research, investing in biotech companies, building shared infrastructure, and connecting the right people at the right time. And the results are starting to show. They have a growing portfolio of investments, dedicated clinical trial infrastructure, and a seat at the table in deals that are moving the needle for patients who have waited long enough.
Publisher
Beyond Biotech - the podcast from Labiotech
Published
July 24, 2026
Duration
40 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Labiotech
Beyond Biotech - the podcast from Labiotech
@beyondbiotechthepodcastfroml
#nonprofit #ecosystem #cureepidermolysisbullosa
